

Message

---

**From:** McClure, Peter [mcclure@srcinc.com]  
**Sent:** 5/5/2014 2:55:28 PM  
**To:** Hogan, Karen [Hogan.Karen@epa.gov]; Pratt, Margaret [pratt.margaret@epa.gov]  
**CC:** Chiu, Weihsueh [Chiu.Weihsueh@epa.gov]; Flowers, Lynn [Flowers.Lynn@epa.gov]; Rice, Glenn [rice.glenn@epa.gov]; Melia, Julie [jmelia@srcinc.com]; Carlson-Lynch, Heather [hclynch@srcinc.com]  
**Subject:** RE: BPA#: EP-BPA-11-C-0018; Contract No. GS-00F-0019L; TO#: EP-B14C-00008: PROPOSED WORK PAHS #16-20 AND 21-25  
**Attachments:** REV 1 BaP data for studies with 0 incidence for PAHs 1-15 SRC 050514.doc

Margaret and Karen,

Attached is a table with information about BaP data availability for 7 datasets for 2 PAHs (anthracene and benz[a]anthracene, among PAHs 1-15) that have "PAH incidence = zero".

Peter

Peter McClure, PhD, DABT  
Senior Toxicologist  
SRC, Inc.  
7502 Round Pond Road  
North Syracuse, New York 13212  
315 452 8420 (T)  
315 452 8440 (F)

---

**From:** McClure, Peter  
**Sent:** Saturday, May 03, 2014 8:32 AM  
**To:** 'Hogan, Karen'; Pratt, Margaret  
**Cc:** Chiu, Weihsueh; Flowers, Lynn; Rice, Glenn; Melia, Julie; Carlson-Lynch, Heather  
**Subject:** RE: BPA#: EP-BPA-11-C-0018; Contract No. GS-00F-0019L; TO#: EP-B14C-00008: PROPOSED WORK PAHS #16-20 AND 21-25

Karen,

Thanks for the clarification.

Going forward, we will adopt the practice of applying more than one "x" in a row if appropriate to the data, and not add any designations for RPFs=0.

Peter

Peter McClure, PhD, DABT  
Senior Toxicologist  
SRC, Inc.  
7502 Round Pond Road  
North Syracuse, New York 13212  
315 452 8420 (T)  
315 452 8440 (F)

---

**From:** Hogan, Karen [<mailto:Hogan.Karen@epa.gov>]

**Sent:** Friday, May 02, 2014 5:30 PM

**To:** McClure, Peter; Pratt, Margaret

**Cc:** Chiu, Weihsueh; Flowers, Lynn; Rice, Glenn; Melia, Julie; Carlson-Lynch, Heather

**Subject:** RE: BPA#: EP-BPA-11-C-0018; Contract No. GS-00F-0019L; TO#: EP-B14C-00008: PROPOSED WORK PAHS #16-20 AND 21-25

Peter et al,

I'm sorry that my comment wasn't clear. I only suggested that when there is no BaP data corresponding to PAH studies without any responses to the PAH, the lack of BaP data should be flagged in these disposition tables. So there can be more than one "x" in each row. I didn't ask for any RPFs of 0 to be entered anywhere.

For any cases with suitable BaP data, but no responses to the levels of the PAH tested, we have to evaluate whether the exposures were high enough to elicit a response before deciding that the RPF is zero. EPA will do this evaluation. Entering RPFs of 0 now would be premature.

The comment was intended as a heads-up that Margaret has to confirm.

We appreciate the quick work! We should be able to return comments on PAHs 6-15 Monday morning.

Have a good weekend,  
Karen

---

**From:** McClure, Peter [<mailto:mcclure@srcinc.com>]

**Sent:** Friday, May 02, 2014 4:31 PM

**To:** Hogan, Karen; Pratt, Margaret

**Cc:** Chiu, Weihsueh; Flowers, Lynn; Rice, Glenn; Melia, Julie; Carlson-Lynch, Heather

**Subject:** RE: BPA#: EP-BPA-11-C-0018; Contract No. GS-00F-0019L; TO#: EP-B14C-00008: PROPOSED WORK PAHS #16-20 AND 21-25

Margaret, Karen et al.

Thanks for your comments. Attached are files with summaries of proposed work for PAHs #16-20 AND 21-25. More to come.

We look forward to your responses.

Peter

Peter McClure, PhD, DABT

Senior Toxicologist

SRC, Inc.

7502 Round Pond Road

North Syracuse, New York 13212

315 452 8420 (T)

315 452 8440 (F)

---

**From:** Hogan, Karen [<mailto:Hogan.Karen@epa.gov>]

**Sent:** Friday, May 02, 2014 11:45 AM

**To:** Pratt, Margaret; McClure, Peter; Melia, Julie; Carlson-Lynch, Heather

**Cc:** Chiu, Weihsueh; Flowers, Lynn; Rice, Glenn

**Subject:** RE: BPA#: EP-BPA-11-C-0018; Contract No. GS-00F-0019L; TO#: EP-B14C-00008: PROPOSED WORK PAHS #1-5

Dear all,

Just a clarification in addition to Margaret's note yesterday. Pending confirmation by Margaret, in the disposition summaries it will be helpful to flag when there is no suitable BaP data in addition to the other flags. In particular, several cases of studies with no tumor incidence for a PAH would seem to lead to a 0 RPF to be averaged with other RPFs, when it's really the lack of BaP data that determines no further work for these. At least through PAH #6, if I'm not misunderstanding anything.

Still good to flag the lack of response; we will characterize where needed whether or not the PAH dose was high enough to see a response given the designs for these studies.

Thanks,  
Karen